Antibiotic resistance in isolates recovered from women with community-acquired urinary tract infections presenting to a tertiary care emergency department

Canadian Journal of Emergency Medicine

Volumn 14, Issue 5, 2012, Pages 295-305

  Filiatrault, Lyne ^a,b   McKay, Rachel M ^c   Patrick, David M ^c   Roscoe, Diane L ^a,b   Quan, Grahame ^a   Brubacher, Jeff ^b   Collins, Ken M ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

Antibiotic resistance; Community acquired; Risk factors; Urinary tract infection

Indexed keywords

AMPICILLIN; CEFALEXIN; CEFALOTIN; CEFAZOLIN; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; TOBRAMYCIN;

AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; CYSTITIS; EMERGENCY WARD; ESCHERICHIA COLI; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; NONHUMAN; PREVALENCE; PYELONEPHRITIS; REVIEW; STAPHYLOCOCCUS AUREUS; TERTIARY HEALTH CARE; URBAN POPULATION; URINARY TRACT INFECTION; URINE CULTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BRITISH COLUMBIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; EMERGENCY SERVICE, HOSPITAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; TERTIARY CARE CENTERS; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84869049080     PISSN: 14818035     EISSN: None     Source Type: Journal    
DOI: 10.2310/8000.2012.120666     Document Type: Review

References (27)

1. Mazzulli T. Resistance trends in urinary tract pathogens and their impact on management. Infect Dis Microbiol Rounds 2002;2:5.
2. Aubin C. Does this woman have an acute uncomplicated urinary tract infection? Ann Emerg Med 2007;49:106-8, doi:10.1016/j.annemergmed.2006.09.022.
3. Seupal R, McDowell C, Bassett R. Urinary tract infection. In: Rowe B, editor. Evidence-based emergency medicine. Chichester (UK): Blackwell Publishing; 2009. p. 412-9.
4. Kunin C. Urinary tract infections: detection, prevention, and management. Baltimore: Williams & Wilkins; 1997.
5. Ikaheimo R, Siitonen A, Heiskanen T, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 1996;22:91-9, doi:10.1093/clinids/22.1.91.
6. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women. JAMA 2000;283:1583-90, doi:10.1001/jama.283.12.1583.
7. Raz R, Chazan B, Kennes Y, et al. Israeli Urinary Tract Infection Group. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX resistant uropathogens. Clin Infect Dis 2002;34:1165-9, doi:10.1086/339812.
8. McNulty CAM, Richards J, Livermore DM, et al. Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. J Antimicrob Chemother 2006;58:1000-8, doi:10.1093/jac/dkl368.
9. Alam MF, Cohen D, Butler C, et al. The additional costs of antibiotics and re-consultations for antibiotic-resistant Escherichia coli urinary tract infections managed in general practice. Int J Antimicrob Agents 2009;33:255-7, doi:10.1016/j.ijantimicag.2008.08.027.
10. Karlowsky JA, Kelly LJ, Thornsberry C, et al. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002;46:2540-5, doi:10.1128/AAC.46.8.2540-2545.2002.
11. Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006;27:468-75, doi:10.1016/j.ijantimicag.2006.02.009.
12. Drekonja DM, Johnson JR. Urinary tract infections. Prim Care 2008;35:345-67, doi:10.1016/j.pop.2008.01.001.
13. Abrahamian FM, Moran GJ, Talan DA. Urinary tract infections in the emergency department. Infect Dis Clin North Am 2008;22:73-87, doi:10.1016/j.idc.2007.10.002.
14. Nicolle LE. Epidemiology of urinary tract infections. Clin Microbiol Newsl 2002;24:135-40, doi:10.1016/S0196-4399 (02)80035-6.
15. Hooton TM, Besser R, Foxman B, et al. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis 2004; 39:75-80, doi:10.1086/422145.
16. Miller LG, Tang AW. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin Proc 2004;79:1048, doi:10.4065/79.8.1048.
17. Carson C, Naber KG. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections. Drugs 2004;64:1359-73, doi:10.2165/00003495-200464120-00007.
18. Gilbert EH, Lowenstein SR, Koziol-McLain J, et al. Chart reviews in emergency medicine research: where are the methods? Ann Emerg Med 1996;27:305-8, doi:10.1016/S0196-0644(96)70264-0.
19. Worster A, Bledsoe RD, Cleve P, et al. Reassessing the methods of medical record review studies in emergency medicine research. Ann Emerg Med 2005;45:448-51, doi: 10.1016/j.annemergmed.2004.11.021.
20. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 2001;135:41-50.
21. Wagenlehner FME, Naber KG. Suitable antibacterial substances for the treatment of urinary tract infections. Antiinfect Agents Med Chem 2006;5:309-29.
22. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20, doi:10.1093/cid/ciq257.
23. McIsaac WJ, Mazzulli T, Permaul J, et al. Communityacquired antibiotic resistance in urinary isolates from adult women in Canada. Can J Infect Dis Med Microbiol 2006;17: 337-40.
24. Patrick DM, Hutchinson J. Antibiotic use and population ecology: how you can reduce your "resistance footprint." CMAJ 2009;180:416-21.
25. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004;38:1148-52.
26. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis 2002;34:1061-6, doi:10.1086/339491.
27. Talan DA, Krishnadasan A, Abrahamian FM, et al. EMERGEncy ID NET Study Group. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008;47:1150-8, doi:10.1086/592250.